Gary A Ulaner1,2, Raychel Castillo3,4, Jonathan Wills5, Mithat Gönen6, Debra A Goldman6. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ulanerg@mskcc.org. 2. Department of Radiology, Weill Cornell Medical College, New York, NY, USA. ulanerg@mskcc.org. 3. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Radiology, Weill Cornell Medical College, New York, NY, USA. 5. Department of Information Systems, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
OBJECTIVES: This study assesses 18F-FDG-PET/CT for patients with newly diagnosed estrogen receptor-positive/human epidermal growth factor receptor-negative (ER+/HER2-) and human epidermal growth factor receptor-positive (HER2+) breast cancer. METHODS: In this Institutional Review Board-approved retrospective study, our Healthcare Information System was screened for patients with ER+/HER2- and HER2+ breast cancer who underwent 18F-FDG-PET/CT prior to systemic or radiation therapy. The initial stage was determined from mammography, ultrasound, magnetic resonance imaging, and/or surgery.18F-FDG-PET/CT was evaluated to identify unsuspected extra-axillary regional nodal and distant metastases. The proportion of patients upstaged overall and stratified by stage and receptor phenotypes was calculated along with confidence intervals (CI). RESULTS: A total of 238 patients with ER+/HER2- and 245 patients with HER2+ who met inclusion criteria were evaluated. For patients with ER+/HER2-breast cancer, 18F-FDG-PET/CT revealed unsuspected distant metastases in 3/71 (4%) initial stage IIA, 13/95 (14%) stage IIB, and 15/57 (26%) stage III. For patients with HER2+ breast cancer, 18F-FDG-PET/CT revealed unsuspected distant metastases in 3/72 (4%) initial stage IIA, 13/93 (14%) stage IIB, and 13/59 (22%) stage III. The overall upstaging rate for IIB was 14% (95% confidence interval (CI): 9-20%). CONCLUSIONS: 18F-FDG-PET/CT revealed distant metastases in 14% (95% CI: 9-20%) of patients with stage IIB ER+/HER2- and HER2+ breast cancer, which is similar to upstaging rates previously seen in patients with stage IIB triple-negative breast cancer (15%, 95% CI: 9-24%). The detection of unsuspected distant metastases in these patients alters treatment and prognosis. NCCN guidelines should consider adding patients with stage IIB breast cancer for consideration of systemic staging with 18F-FDG-PET/CT at the time of initial diagnosis.
OBJECTIVES: This study assesses 18F-FDG-PET/CT for patients with newly diagnosed estrogen receptor-positive/humanepidermal growth factor receptor-negative (ER+/HER2-) and humanepidermal growth factor receptor-positive (HER2+) breast cancer. METHODS: In this Institutional Review Board-approved retrospective study, our Healthcare Information System was screened for patients with ER+/HER2- and HER2+ breast cancer who underwent 18F-FDG-PET/CT prior to systemic or radiation therapy. The initial stage was determined from mammography, ultrasound, magnetic resonance imaging, and/or surgery.18F-FDG-PET/CT was evaluated to identify unsuspected extra-axillary regional nodal and distant metastases. The proportion of patients upstaged overall and stratified by stage and receptor phenotypes was calculated along with confidence intervals (CI). RESULTS: A total of 238 patients with ER+/HER2- and 245 patients with HER2+ who met inclusion criteria were evaluated. For patients with ER+/HER2-breast cancer, 18F-FDG-PET/CT revealed unsuspected distant metastases in 3/71 (4%) initial stage IIA, 13/95 (14%) stage IIB, and 15/57 (26%) stage III. For patients with HER2+ breast cancer, 18F-FDG-PET/CT revealed unsuspected distant metastases in 3/72 (4%) initial stage IIA, 13/93 (14%) stage IIB, and 13/59 (22%) stage III. The overall upstaging rate for IIB was 14% (95% confidence interval (CI): 9-20%). CONCLUSIONS: 18F-FDG-PET/CT revealed distant metastases in 14% (95% CI: 9-20%) of patients with stage IIB ER+/HER2- and HER2+ breast cancer, which is similar to upstaging rates previously seen in patients with stage IIB triple-negative breast cancer (15%, 95% CI: 9-24%). The detection of unsuspected distant metastases in these patients alters treatment and prognosis. NCCN guidelines should consider adding patients with stage IIB breast cancer for consideration of systemic staging with 18F-FDG-PET/CT at the time of initial diagnosis.
Entities:
Keywords:
18F–FDGPET/CT; Breast cancer; Estrogen receptor; Human epidermal growth factor receptor 2
Authors: Molly P Hogan; Debra A Goldman; Brittany Dashevsky; Christopher C Riedl; Mithat Gönen; Joseph R Osborne; Maxine Jochelson; Clifford Hudis; Monica Morrow; Gary A Ulaner Journal: J Nucl Med Date: 2015-08-20 Impact factor: 10.057
Authors: Nancy U Lin; Ann Vanderplas; Melissa E Hughes; Richard L Theriault; Stephen B Edge; Yu-Ning Wong; Douglas W Blayney; Joyce C Niland; Eric P Winer; Jane C Weeks Journal: Cancer Date: 2012-04-27 Impact factor: 6.860
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: William J Gradishar; Benjamin O Anderson; Ron Balassanian; Sarah L Blair; Harold J Burstein; Amy Cyr; Anthony D Elias; William B Farrar; Andres Forero; Sharon Hermes Giordano; Matthew Goetz; Lori J Goldstein; Clifford A Hudis; Steven J Isakoff; P Kelly Marcom; Ingrid A Mayer; Beryl McCormick; Meena Moran; Sameer A Patel; Lori J Pierce; Elizabeth C Reed; Kilian E Salerno; Lee S Schwartzberg; Karen Lisa Smith; Mary Lou Smith; Hatem Soliman; George Somlo; Melinda Telli; John H Ward; Dorothy A Shead; Rashmi Kumar Journal: J Natl Compr Canc Netw Date: 2016-03 Impact factor: 11.908
Authors: Gary A Ulaner; Raychel Castillo; Debra A Goldman; Jonathan Wills; Christopher C Riedl; Katja Pinker-Domenig; Maxine S Jochelson; Mithat Gönen Journal: Eur J Nucl Med Mol Imaging Date: 2016-04-30 Impact factor: 9.236
Authors: Christopher C Riedl; Elina Slobod; Maxine Jochelson; Monica Morrow; Debra A Goldman; Mithat Gonen; Wolfgang A Weber; Gary A Ulaner Journal: J Nucl Med Date: 2014-09-11 Impact factor: 10.057
Authors: Jill Gluskin; Sarah Eliades; Aradhna Raj; Varadan Sevilimedu; Richard Kinh Gian Do Journal: Clin Imaging Date: 2022-02-16 Impact factor: 2.420
Authors: Nils Martin Bruckmann; Lino M Sawicki; Julian Kirchner; Ole Martin; Lale Umutlu; Ken Herrmann; Wolfgang Fendler; Ann-Kathrin Bittner; Oliver Hoffmann; Svjetlana Mohrmann; Frederic Dietzel; Marc Ingenwerth; Benedikt M Schaarschmidt; Yan Li; Bernd Kowall; Andreas Stang; Gerald Antoch; Christian Buchbender Journal: Eur J Nucl Med Mol Imaging Date: 2020-04-24 Impact factor: 9.236